Molinelli Elisa, Campanati Anna, Brisigotti Valerio, Offidani Annamaria
Dermatology Unit Department of Clinical and Molecular Sciences, Polytechnic Marche University, Ancona, Italy.
Curr Pharm Biotechnol. 2017;18(12):964-978. doi: 10.2174/1389201019666180103140643.
Psoriasis is a chronic immune-mediated inflammatory skin disorder that is estimated to affect 2-3% of the general population. The IL-23/IL-17 axis is currently considered to be crucial in the pathogenesis of psoriasis.
Biologics licensed for psoriasis include the TNFα inhibitors (infliximab, adalimumab, etanercept), the interleukin (IL)-12/23 monoclonal antibody (ustekinumab), and IL-17 inhibitor (secukinumab, ixekizumab).
In this section, we analyse the role of IL-12, IL-23, and IL-17 in psoriasis and evaluated the efficacy and safety of biologic therapies targeting this cytokine.
Dosing regimens, administration modality, and pharmacodynamics profiles of currently available anti-IL-12/IL-23 and IL-17 inhibitors are also examined.
银屑病是一种慢性免疫介导的炎症性皮肤病，据估计影响普通人群的2%-3%。目前认为IL-23/IL-17轴在银屑病的发病机制中至关重要。
已获许可用于银屑病治疗的生物制剂包括肿瘤坏死因子α（TNFα）抑制剂（英夫利昔单抗、阿达木单抗、依那西普）、白细胞介素（IL）-12/23单克隆抗体（乌司奴单抗）和IL-17抑制剂（司库奇尤单抗、依奇珠单抗）。
在本节中，我们分析了IL-12、IL-23和IL-17在银屑病中的作用，并评估了针对这些细胞因子的生物治疗的疗效和安全性。
还研究了目前可用的抗IL-12/IL-23和IL-17抑制剂的给药方案、给药方式和药效学特征。
